Close Menu

More articles about Research & Discovery

Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.

The company uses a combination of transcriptomic and proteomic data combined with machine-learning analysis to identify immune profiles linked to disease.

The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.

The study aims to enroll 20,000 existing Biobank participants, as well as their adult children and grandchildren, from England, Scotland, and Wales.

The research suggests that pangolins are natural hosts of Betacoronaviruses but does not support the idea that SARS-CoV-2 emerged directly from pangolins.

The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.

Ancient sequences from two-dozen individuals revealed genetically distinct populations from northern and southern East Asia that ultimately met and mixed.

Erisyon will use its single-molecule protein sequencing technology to detect and validate biomarkers for early detection of Parkinson's disease.

Researchers uncovered gene expression signatures that can predict whether someone may be protected by a malaria vaccine even before it is given.

The variant also appears to be under positive selection and is more common among coastal Peruvians.

Illumina will sequence 35,000 whole genomes for the Genetics of Mortality in Critical Care (GenOMICC) study and will provide an in-kind contribution.

Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.

A Broad Institute-led team found that differences by ancestry could affect not only how cancer develops but also treatment approaches.

The firm said its test is one-thousandfold  more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.

According to the company, its ArrayPlex platform can screen patient samples for anti-SARS-CoV-2 antibodies at a rate of 18,000 samples per instrument per day.

The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.

Fluidigm's mass cytometry and microfluidics research product sales were negatively impacted by the COVID-19 pandemic.

An international team of researchers analyzed genome-wide data from 89 individuals to reconstruct the population history of the region.

Researchers investigated how well four polygenic risk scores for coronary heart disease performed in three racial or ethnic groups in the US.

The informatics firm is working on an RUO COVID-19 susceptibility risk score to inform researchers and policymakers itching to restart the US economy.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.